Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

BridgeBio Pharma (BBIO) EPS (Weighted Average and Diluted) (2020 - 2025)

BridgeBio Pharma's EPS (Weighted Average and Diluted) history spans 6 years, with the latest figure at -$0.99 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 30.28% year-over-year to -$0.99; the TTM value through Dec 2025 reached -$3.78, down 31.71%, while the annual FY2025 figure was -$3.78, 31.25% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.99 at BridgeBio Pharma, down from -$0.95 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.07 in Q2 2022 and bottomed at -$1.42 in Q4 2024.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.95 (2025), against an average of -$0.87.
  • The largest annual shift saw EPS (Weighted Average and Diluted) soared 89.63% in 2022 before it tumbled 1300.0% in 2023.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.02 in 2021, then rose by 9.8% to -$0.92 in 2022, then dropped by 4.35% to -$0.96 in 2023, then tumbled by 47.92% to -$1.42 in 2024, then skyrocketed by 30.28% to -$0.99 in 2025.
  • Per Business Quant, the three most recent readings for BBIO's EPS (Weighted Average and Diluted) are -$0.99 (Q4 2025), -$0.95 (Q3 2025), and -$0.96 (Q2 2025).